For patients with decreased tear production presumed to be
due to ocular infl ammation associated with chronic dry eye
Your patients can make
more of their own tears
with continued use
twice a day, every day
1
89% to 96% of commercial
and Part D patients have
preferred or covered status
2
*
RESTASIS
®
is the #1 dispensed FDA-approved, branded eye drop
3
INDICATIONS AND USAGE: RESTASIS
®
and RESTASIS MultiDose
®
ophthalmic emulsion are indicated to increase tear production in
patients whose tear production is presumed to be suppressed due to ocular infl ammation associated with keratoconjunctivitis sicca.
Increased tear production was not seen in patients currently taking topical anti-infl ammatory drugs or using punctal plugs.
IMPORTANT SAFETY INFORMATION
CONTRAINDICATIONS: RESTASIS
®
and RESTASIS MultiDose
®
are contraindicated in patients with known or suspected
hypersensitivity to any of the ingredients in the formulation.
WARNINGS AND PRECAUTIONS
POTENTIAL FOR EYE INJURY AND CONTAMINATION: Be careful not to touch the container tip to your eye or other surfaces to
avoid potential for eye injury and contamination.
USE WITH CONTACT LENSES: RESTASIS
®
and RESTASIS MultiDose
®
should not be administered while wearing contact lenses. If
contact lenses are worn, they should be removed prior to the administration of the emulsion. Lenses may be reinserted 15 minutes
following administration of RESTASIS
®
and RESTASIS MultiDose
®
ophthalmic emulsion.
ADVERSE REACTIONS: In clinical trials, the most common adverse reaction following the use of cyclosporine ophthalmic emulsion
0.05% was ocular burning (upon instillation)—17%. Other reactions reported in 1% to 5% of patients included conjunctival hyperemia,
discharge, epiphora, eye pain, foreign body sensation, pruritus, stinging, and visual disturbance (most often blurring).
PLEASE SEE NEXT PAGE FOR A BRIEF SUMMARY OF THE FULL PRODUCT INFORMATION.
REFERENCES: 1. RESTASIS
®
Prescribing Information, June 2017. 2. Managed Markets Insight & Technology, LLC, Database as of December 2018.
3. IQVIA Prescription Audit, June 2019.
*Based on 5,932 plans/228,313,851 commercial lives.
© 2019 Allergan. All rights reserved. All trademarks are the property of their respective owners. RES125106 06/19
